deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT07034963

Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care

Sponsor: The First Affiliated Hospital of Xiamen University

Conditions Intrauterine Polyp Intrauterine Synechiae
Interventions Determine the ED50 and ED95 of esketamine Intravenous remifentanil 1μg∙kg-1 Intravenous the dose of esketamine ED95
Updated 2 times since 2025 Last updated: Jul 21, 2025 Started: Jun 26, 2025 Primary completion: Jun 30, 2028 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07034963, this PHASE1/PHASE2 trial focuses on Intrauterine Polyp and Intrauterine Synechiae and remains ongoing. Sponsored by The First Affiliated Hospital of Xiamen University, it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshotActive Not Recruiting~Aug 2025 – present · 12 months · monthly snapshotActive Not Recruiting

Change History

2 versions recorded

  1. Aug 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Jul 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    First recorded

Jun 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The First Affiliated Hospital of Xiamen University
Data source: The First Affiliated Hospital of Xiamen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations